ABL Bio

298380.KQ

32.57 USD

2.54

+8.46%

Overview

Last close

32.57 usd

Market cap

1.82B usd

52 week high

171.55 usd

52 week low

30.03 usd

Target price

202.37 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

70.7945

Price/Book Value

16.5872

Enterprise Value

2.05B usd

EV/Revenue

79.7048

EV/EBITDA

-32.1061

Key financials

Revenue TTM

25.70M usd

Gross Profit TTM

25.61M usd

EBITDA TTM

-61.60M usd

Earnings per Share

-1.05 usd

Dividend

N/A usd

Total assets

176.88M usd

Net debt

N/A usd

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.